Condition: endometrial adenoacanthoma


rs1057519794 in EGFR gene and endometrial adenoacanthoma PMID 22885469 2012 Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.

rs1057519045 in FGFR2 gene and endometrial adenoacanthoma PMID 23908597 2013 The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.

PMID 22238366 2012 Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.

PMID 23002168 2012 FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.

PMID 18552176 2008 Drug-sensitive FGFR2 mutations in endometrial carcinoma.

rs1057519801 in PIK3R2 gene and endometrial adenoacanthoma PMID 21984976 2011 High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.